Cargando…
A meta-analysis comparing hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma
BACKGROUND: The majority of patients with hepatocellular carcinoma (HCC) are diagnosed in an advanced stage. Although sorafenib is recommended as the standard treatment for advanced HCC, its efficacy is limited. In some studies, hepatic arterial infusion chemotherapy has demonstrated a significant t...
Autores principales: | Yan, Leye, Lin, Junqing, Ke, Kun, Wu, Zhengzhong, Huang, Jingyao, Huang, Ning, Yang, Weizhu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841468/ https://www.ncbi.nlm.nih.gov/pubmed/35261888 http://dx.doi.org/10.21037/tcr-21-1839 |
Ejemplares similares
-
Sorafenib plus hepatic arterial infusion chemotherapy with oxaliplatin versus sorafenib alone for advanced hepatocellular carcinoma
por: Zhao, Yang, et al.
Publicado: (2019) -
Treatment strategies for advanced hepatocellular carcinoma: Sorafenib vs hepatic arterial infusion chemotherapy
por: Saeki, Issei, et al.
Publicado: (2018) -
Hepatic Arterial Infusion Chemotherapy of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Sorafenib as Initial Treatment for Advanced Hepatocellular Carcinoma
por: Liang, Run-Bin, et al.
Publicado: (2021) -
Constitutive TDO2 expression promotes liver cancer progression by an autocrine IL-6 signaling pathway
por: Wu, Zhengzhong, et al.
Publicado: (2021) -
Transthyretin promotes the invasion of combined hepatocellular cholangiocarcinoma by tumor‐associated macrophages
por: Ke, Kun, et al.
Publicado: (2023)